BioSpace News Archive

BioCapital

Salubris Biotherapeutics Announces $32 Million Financing to Advance Novel Complex Biologics for Cardiovascular, Oncology, and Neurodegenerative Diseases

Salubris Biotherapeutics, Inc. today announced it received $32 million in financing from China-based Shenzhen Salubris Pharmaceuticals Co., Ltd.

March 7, 2022
·
5 min read
Business

Scholar Rock Reports Full Year 2021 Financial Results and Highlights Business Progress

Scholar Rock today reported financial results for the full year ended December 31, 2021, and highlighted recent progress and upcoming milestones for its pipeline programs.

March 7, 2022
·
11 min read
Genetown

Bone Biologics Enters into Supply Agreement with MTF Biologics for Demineralized Bone Matrix

Bone Biologics Corporation announces it has entered into a supply agreement with MTF Biologics for demineralized bone matrix (DBM).

March 7, 2022
·
4 min read
Genetown

Akili to Present at Cowen’s 42nd Annual Health Care Conference

Akili Interactive today announced that management will present at Cowen’s 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 12:50 p.m. E.T.

March 7, 2022
·
5 min read
Drug Development

Repare Therapeutics Presents RP-3500 Dose Selection Phase 1 Monotherapy Safety Data from the Phase 1/2 TRESR Clinical Trial at the 2022 ESMO Targeted Anticancer Therapies Congress

Repare Therapeutics Inc. today announced the presentation of monotherapy dose selection and safety data from its Phase 1/2 TRESR (Treatment Enabled by SNIPRx) clinical trial of RP-3500 at the 2022 ESMO Targeted Anticancer Therapies (TAT) Congress.

March 7, 2022
·
6 min read
Microbiotica Raises £50m ($67m) to Advance Pipeline of Microbiome-based Therapeutics

Microbiotica today announced the completion of a £50 million ($67 million) Series B financing round – the largest microbiome-related financing in Europe to date.

March 7, 2022
·
9 min read
Business

Centessa Pharmaceuticals Expands Management Team and Adds to Extensive Development Expertise

Centessa Pharmaceuticals plc today announced that Antoine Yver, MD, MSc, has been appointed Executive Vice President and Chairman of Development.

March 7, 2022
·
5 min read
FDA

Harpoon Therapeutics Granted Orphan Drug Designation for HPN328 for Treatment of Small Cell Lung Cancer

Harpoon Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for HPN328, a delta like ligand 3- (DLL3) targeting TriTAC ® , for the treatment of small cell lung cancer (SCLC).

March 7, 2022
·
6 min read
Business

Day One Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Progress

Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced its fourth quarter and full year 2021 financial results and highlighted recent corporate achievements.

March 7, 2022
·
9 min read
Statera Biopharma Advances Next-Gen Proprietary Compositions Based on STAT-200 Platform

Statera Biopharma, Inc. today announced advancement of its next-gen research activities that builds upon the immune modulation activity of STAT-200 on Toll-Like Receptors (TLRs) to improve drug characteristics and clinical benefit beyond opioid receptors.

March 7, 2022
·
4 min read